The Origins of Thalidomide Heinrich Mückter (14 June 1914 – 22 May 1987) was a German medical doctor, pharmacologist and chemist.
World War II During the Nazi occupation of Poland, Mückter was deputy director of the Kraków Institute for Typhus and Virus Research. Mückter and his colleagues repeatedly experimented on concentration camp prisoners in Buchenwald. Many prisoners died as a result of the experiments. Accused by Polish war crimes prosecutors of conducting medical experiments on concentration camp prisoners and Nazi forced labourers, Mückter escaped arrest and fled back to Germany.
Invention of thalidomide In 1946 Mückter became Head of Research at the Grünenthal pharmaceutical company, where he further developed the infamous drug thalidomide which had been synthesized in 1952 by Chemical Industry Basel. Aggressively-marketed as an over-the-counter sleeping pill and remedy for morning sickness in pregnancy, thalidomide was first made available on 1 October 1957, and it became the second best-selling medication in Germany after Bayer Aspirin. Thalidomide was eventually found to cause miscarriages, severe birth defects in babies whose mothers had taken the medication while pregnant, and severe nerve damage. In January 1968, Mückter was put on trial along with other Grünenthal employees. The trial ended abruptly in April 1970 with a settlement. Mückter was never charged in relation to his role in experiments on concentration camp prisoners, nor his role in the thalidomide scandal. He died on 22 May 1987. https://en.wikipedia.org/wiki/Heinrich_M%C3%BCckter
II. Thalidomide’s Chemical Properties and Effects Thalidomide’s molecular formula is C13H10N2O4, making it a relatively small and unassuming structure. It exists in two unique spatial arrangements, thus it can be further classified as (R) or (S). The prescription medication distributed during this time comprised a mixture of these two forms. The (R) form is known to have sedative and hypnotic properties while the (S) form is known to be teratogenic - if someone is exposed to the (S) form of thalidomide during pregnancy, it can interfere with normal fetal development and lead to congenital disorders in the child. The properties of both forms put together, as was the case in the 20th century commercial drug, simultaneously treated nausea and morning sickness in pregnant women while causing physical malformations in their children.
